Spotlight on Back to School & FDA: a BioCentury podcast
Plus, BioCentury’s monthly look at top translational topics
On the latest BioCentury This Week podcast, BioCentury’s editors focus on the key takeaways from the 2021 Back to School package and discuss why they believe accelerated approval is poised for change. The editors also discuss the implications of surprise resignations by top vaccine reviewers at FDA’s CBER, and what’s at stake for FDA and biopharma companies with Congress’ investigations into the agency’s approval of Alzheimer’s therapy Aduhelm aducanumab-avwa. And, returning for her monthly look at hot topics in translational news, Senior Editor Karen Tkach Tuzman discusses what’s on tap for the Distillery.